I am currently the President of Scicon Solutions, a scientific consulting and contract research business that provides drug discovery services to pharmaceutical and biotech companies. Services include: Medicinal Chemistry consulting (to help guide project teams to identify high-quality drug candidates) and Discovery Research operational/management support (to help drive continuous improvement across functional and therapeutic areas to facilitate Discovery Research initiatives), and Expert Witness services (to provide input and assistance regarding intellectual property disputes) (https://sciconsolutions.com/). In addition to consulting, I serve on two Scientific Advisory Boards: ADRx, a privately funded preclinical stage biotechnology company focused on transforming atomic structures into small molecule therapies to treat Alzheimer’s, ALS, and Parkinson’s Disease (https://www.adrxpharma.com/); and BrainStorm Therapeutics, a biotechnology company developing a proprietary "human-first" CNS drug discovery platform utilizing patient iPSC-derived models of brain disease to discover molecules that restore synaptic network function and halt, prevent, or reverse neurodegeneration (https://www.brainstormtherapeutics.org/). Prior to these positions, I was a Scientific Executive Director in the Therapeutic Discovery department at Amgen in Thousand Oaks, California, and I also taught Organic Chemistry as an adjunct professor in the Chemistry Department at Cal Lutheran University. I have over 35 years of drug discovery and development experience in the pharmaceutical and biotechnology sector with Amgen, Glaxo Wellcome, and Burroughs Wellcome, where I held positions of increasing responsibility. At Burroughs Wellcome and Glaxo Wellcome, my research efforts were directed toward the development of therapeutic agents to treat schizophrenia, hypertension, emesis, and viral infections. After my time at Glaxo Wellcome, I was recruited to Amgen to participate in the building of their small molecule drug discovery department and its infrastructure. While at Amgen, I led and managed various projects, from drug discovery to clinical trials, in the areas of oncology, inflammation, metabolic disorders, and neurobiology, resulting in the identification of eleven clinical candidates. With over 235 publications, presentations, and patents, I have demonstrated a consistent track record of delivering therapeutic candidates for pre-clinical and clinical evaluation. In addition to my research responsibilities, I served as the Amgen Thousand Oaks (ATO)-B29 Site Head for safety.